Text Size

Symbicort in Chronic Obstructive Pulmonary Disease (SYMBOL)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00611520
First received: January 29, 2008
Last updated: January 27, 2011
Last verified: January 2011
History of Changes
  Purpose

Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. pneumologists and internists) are asked to document relevant data related to the budesonide/formoterole therapy in patients with COPD.


Condition
Chronic Obstructive Pulmonary Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Symbicort in Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Secondary Outcome Measures:
  • to get further insight into the details of the use , dosage scheme and duration of treatment with budesonide /formoterol in this population

Enrollment: 64730
Study Start Date: September 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patients with COPD treated with budesonide/formoterol

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients

Criteria

Inclusion Criteria:

  • Patients with COPD treated with budesonide/formoterol

Exclusion Criteria:

  • limitations; possible risks; warnings; contraindications mentioned in the SPC.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00611520

Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Kai Richter, MD Medical Department AstraZeneca Germany
  More Information

No publications provided

Responsible Party: Dr Kai Richter, AstraZeneca Germany
ClinicalTrials.gov Identifier: NCT00611520     History of Changes
Other Study ID Numbers: 1312005009
Study First Received: January 29, 2008
Last Updated: January 27, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by AstraZeneca:
treatment of COPD
related to the budesonide/formoterole therapy in patients with COPD.

Additional relevant MeSH terms:
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases
 Symbicort
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 19, 2013